Sporadic Pancreatic Polypeptide Secreting Tumors (PPomas) of the Pancreas

Kuo, Samuel; Gananadha, Sivakumar; Scarlett, Christopher J.; Gill, Anthony J.; Smith, Ross C.

doi:10.1007/s00268-008-9499-7

Cited by 30 publications

(26 citation statements)

References 52 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5 However, increased CEA is not typically associated with neuroendocrine tumor of the pancreas. A review of the literature could only identify 2 neuroendocrine tumors of the pancreas associated with abnormal CEA expression; 1 patient had a very slightly increased serum CEA (7.4 ng/mL) seen in the context of a sporadic pancreatic polypeptidesecreting tumor, 6 and a second patient with a cystic neuroendocrine tumor of the pancreas had increased CEA (absolute value not provided) in the cyst fluid. 3 There were also several case reports of pancreatic cancers with multilineage differentiation with both ductal and neuroendocrine components in which CEA was found to be expressed in the ductal component of the tumor.…”

Section: Discussionmentioning

confidence: 96%

Cyst fluid carcinoembryonic antigen in the investigation of cystic neuroendocrine tumors of the pancreas

Croagh

Forde

Boulton

et al. 2011

Gastrointestinal Endoscopy

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 96%

Cyst fluid carcinoembryonic antigen in the investigation of cystic neuroendocrine tumors of the pancreas

Croagh

Forde

Boulton

et al. 2011

Gastrointestinal Endoscopy

View full text Add to dashboard Cite

“…Non-functioning PNETs produce and secrete hormones, but the quantity and the biological activity of these hormones do not produce a distinct syndrome[142]–[144]. Non-functioning PNETs result in non-specific symptoms resulting from tumor mass effects.…”

Section: Specific Types Of Pancreatic Neuroendocrine Tumorsmentioning

confidence: 99%

Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment

Ro¹,

Chai²,

Yu³

et al. 2013

Chin J Cancer

138

130

View full text Add to dashboard Cite

Pancreatic neuroendocrine tumors (PNETs), a group of endocrine tumors arising in the pancreas, are among the most common neuroendocrine tumors. The genetic causes of familial and sporadic PNETs are somewhat understood, but their molecular pathogenesis remains unknown. Most PNETs are indolent but have malignant potential. The biological behavior of an individual PNET is unpredictable; higher tumor grade, lymph node and liver metastasis, and larger tumor size generally indicate a less favorable prognosis. Endocrine testing, imaging, and histological evidence are necessary to accurately diagnose PNETs. A 4-pronged aggressive treatment approach consisting of surgery, locoregional therapy, systemic therapy, and complication control has become popular in academic centers around the world. The optimal application of the multiple systemic therapeutic modalities is under development; efficacy, safety, availability, and cost should be considered when treating a specific patient. The clinical presentation, diagnosis, and treatment of specific types of PNETs and familial PNET syndromes, including the novel Mahvash disease, are summarized.

show abstract

“…PNETs commonly secrete pancreatic polypeptide (PP) and it can be used as a marker in nonfunctional tumors [84]. PNETs secreting PP alone do not cause a distinct syndrome, but PP can be used as a marker following resection [85]. According to one study, the combination of PP and CgA improved the diagnostic sensitivity compared with CgA alone, especially in nonfunctional PNETs [86].…”

Section: Pancreatic Polypeptidementioning

confidence: 95%

Circulating Tumor Markers in Patients with Neuroendocrine Tumors – a Clinical Perspective

Halfdanarson

Howe

Haraldsdóttir

et al. 2015

Int. J. Endo. Oncol.

View full text Add to dashboard Cite

Neuroendocrine tumors (NETs) are uncommon malignancies with a very diverse presentation and prognosis. Patients with NETs frequently have circulating tumor biomarkers that may aid in the diagnosis and help with prognostication. The most commonly used and best studied marker is chromogranin A, which appears to reflect the tumor burden and is useful at the time of diagnosis, and to monitor for recurrence after resection as well as to assess response to systemic therapy. Despite being the best studied marker, chromogranin A has significant limitations. Multiple other biomarkers are in use, but most have not been studied well and need further validation before being recommended for clinical practice. We review both established and novel circulating biomarkers, and highlight some of the limitations of tumor marker use in patients with NETs.

show abstract

Sporadic Pancreatic Polypeptide Secreting Tumors (PPomas) of the Pancreas

Abstract: Resection of sporadic PPomas presenting as a solitary well-defined mass with benign histological features results in good long-term survival.

Cited by 30 publications

References 52 publications

Cyst fluid carcinoembryonic antigen in the investigation of cystic neuroendocrine tumors of the pancreas

Cyst fluid carcinoembryonic antigen in the investigation of cystic neuroendocrine tumors of the pancreas

Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment

Circulating Tumor Markers in Patients with Neuroendocrine Tumors – a Clinical Perspective

Contact Info

Product

Resources

About